Interferon receptor expression in multiple sclerosis patients

Journal of Neuroimmunology

Volumn 183, Issue 1-2, 2007, Pages 225-231

  Oliver, Begoña ^a   Mayorga, Cristobalina ^a   Fernández, Victoria ^a   Leyva, Laura ^a   León, Antonio ^a   Luque, Gloria ^a   López, Juan C ^a   Tamayo, Jose A ^a   Pinto Medel, Maria J ^a   de Ramon, Enrique ^a   Blanco, Eva ^a   Alonso, Ana ^a   Fernández, Oscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

IFNAR; Interferon beta; Multiple sclerosis; MxA

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA1 INTERFERON RECEPTOR; ALPHA2 INTERFERON RECEPTOR; BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; INTERFERON RECEPTOR; MYXOVIRUS RESISTANCE PROTEIN A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TREATMENT RESPONSE;

ADULT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, INTERFERON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33846781532     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.11.010     Document Type: Article

References (40)

1. Antonelli G., Bagnato F., Pozzilli C., et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J. Interferon Cytokine Res. 18 (1998) 345-350
2. Bertolotto A., Gilli F., Sala A., et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60 (2003) 634-639
3. Branca A.A., and Baglioni C. Down-regulation of the interferon receptor. J. Biol. Chem. 257 (1982) 13197-13200
4. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann. Biochem. 162 (1987) 156-159
5. Cohen B.A., Khan O., Jeffery D.R., et al. Identifying and treating patients with suboptimal responses. Neurology 63 (2004) S33-S40
6. Constantinescu S.N., Croze E., Murti A., et al. Expression and signalling specificity of the IFNAR chain of the type I interferon receptor complex. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 10487-10491
7. Croze E., Russell-Harde D., Wagner T.C., et al. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. J. Biol. Chem. 271 (1996) 33165-33168
8. Fernández O., Mayorga C., Luque G., et al. Study of binding and neutralising antibodies to IFN-beta in two groups of relapsing-remitting multiple sclerosis patients treated with IFN-beta-1a and IFN-beta-1b. J. Neurol. 248 (2001) 383-388
9. a edición (2005), McGraw-Hill-Interamericana, Madrid 53
10. Freedman M.S., Patry D.G., Grand'Maison F., et al. Treatment optimisation in multiple sclerosis. Can. J. Neurol. Sci. 31 (2004) 157-168
11. Fukuda R., Ishimura N., Kushiyama Y., et al. Effectiveness of interferon-alfa therapy in chronic hepatitis C is associated with the amount of interferon-alfa receptor mRNA in the liver. J. Hepatol. 26 (1997) 455-461
12. Ito K., Tanaka H., Ito T., et al. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur. J. Haematol. 73 (2004) 91-205
13. Joe F., and Lau B.A. Mechanisms of type I Interferon cell signalling and STAT-mediated transcriptional responses. Mt. Sinai J. Med. 69 3 (2002) (May)
14. Kracke A., von Wussow P., Al-Masri A.N., et al. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 54 1 (2000) 193-199
15. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability scale status. Neurology 33 (1983) 1444-1452
16. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 906-911
17. Massirer K.B., Hirata M.H., Silva A.E.B., et al. Interferon-α receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-α therapy of patients with chronic hepatitis C. Interferon-α therapy of patients with chronic hepatitis C. Braz. J. Med. Biol. Res. 37 (2004) 643-647
18. Mayorga C., Luque G., Romero F., et al. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta. Int. Arch. Allergy Immunol. 118 (1999) 368-371
19. Morita K., Tanaka K., Saito S., et al. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J. Clin. Gastroenterol. 26 (1998) 135-140
20. Novick D., Cohen B., and Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 77 (1994) 391-400
21. Oritani K., Kincade P.W., Zhang C., Tomiyama Y., and Matsuzawa Y. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev. 12 (2001) 337-348
22. Pachner A.R., Oger J., and Palace J. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology 61 (2003) S18-S20
23. Perini P., Calabrese M., Biasi G., and Gallo P. The clinical impact of interferon beta antibodies in relapsing remitting MS. J. Neurol. 251 (2004) 305-309
24. Pestka S., Langer J.A., Zoon K.C., and Samuel C.E. Interferons and their action. Ann. Rev. Biochem. 56 (1987) 727-777
25. Platanias L.C., Uddin S., Domanski P., and Colamonici O.R. Differences in interferon α and β signaling. J. Biol. Chem. 271 (1996) 23630-23633
26. Pogue S.L., Preston B.T., Stalder J., et al. The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. J. Interferon Cytokine Res. 24 (2004) 131-139
27. Polman C.H., and Uitdehaag B.M. Drug treatment of multiple sclerosis. Br. Med. J. 321 (2000) 490-494
28. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-230
29. PRIMS. Prevention on relapses and disability by interferon β-1a subcutaneously in multiple sclerosis. randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
30. PRISMS study group. PRISMS-4: long-term efficacy of interferon-B-1a in relapsing MS. Neurology 56 (2001) 1628-1636
31. Redlich P.N., Hoeprich P.D., Colby, and Grossberg S.E. Antibodies that neutralize human interferon biologic activity recognize a lineal epitope: analysis by synthetic peptide mapping. Proc. Natl. Acad. Sci., U.S.A. 88 (1991) 4040-4044
32. Rudick R.A., Simonian J.A., Alam J.A., et al. Incidence and significance of neutralising antibodies to interferon beta-1a in multiple sclerosis. Neurology 50 (1998) 1266-1272
33. Runkel L., Meier W., Pepinsky B., et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharma. Res. 15 (1998) 641-649
34. Sorensen S., Ross C., Clemmesen K.M., et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
35. The IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
36. The IFN-β Multiple Sclerosis Study Group. Neutralising antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47 (1996) 889-894
37. Trapp B.D., Ransohoff R., and Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12 (1999) 295-302
38. Vartanian T.K., Zamvil S.S., Fox E., and Sorensen P.S. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63 (2004) S42-S49
39. von Wussow P., Jakschies D., Hochkeppel H.K., et al. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur. J. Immunol. 20 (1990) 2015-2019
40. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of multiple sclerosis: a geographically based study. Brain 112 (1989) 133-146